Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi - LARVOL DELTA

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (clinicaltrials.gov) - P2 | N=76 | Completed | Sponsor: Memorial Sloan Kettering Cancer Center | Active, not recruiting ➔ Completed

Trial completion • Oncology

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (clinicaltrials.gov) - P3 | N=1480 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Jul 2024

Trial completion date • Trial primary completion date • CNS Disorders • Infectious Disease • Meningococcal Infections

HOPE II: Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV. (clinicaltrials.gov) - P4 | N=750 | Recruiting | Sponsor: Massachusetts General Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease • Oncology

MEQ00064: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (clinicaltrials.gov) - P3 | N=1528 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Meningococcal Infections • Pediatrics

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (clinicaltrials.gov) - P2 | N=75 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2024 ➔ Jul 2025 | Trial primary completion date: Jul 2024 ➔ Jul 2025

Trial completion date • Trial primary completion date • Oncology

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (clinicaltrials.gov) - P3 | N=1480 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Infectious Disease • Meningococcal Infections

HOPE II: Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV. (clinicaltrials.gov) - P4 | N=750 | Not yet recruiting | Sponsor: Massachusetts General Hospital

New P4 trial • Human Immunodeficiency Virus • Infectious Disease • Oncology

The Bacterial Meningitis Epidemic in Banalia in the Democratic Republic of Congo in 2021. (PubMed, Vaccines (Basel)) - "Despite late detection (two months) and reactive vaccination four months after crossing the epidemic threshold, interventions implemented in Banalia contributed to the control of the epidemic."

Journal • CNS Disorders • Infectious Disease • Meningococcal Infections

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (clinicaltrials.gov) - P3 | N=1480 | Recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Infectious Disease • Meningococcal Infections

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (clinicaltrials.gov) - P3 | N=1480 | Not yet recruiting | Sponsor: CanSino Biologics Inc. | Initiation date: Dec 2023 ➔ Apr 2024

Trial initiation date • CNS Disorders • Infectious Disease • Meningococcal Infections

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (clinicaltrials.gov) - P3 | N=1480 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Infectious Disease • Meningococcal Infections

MET55: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (clinicaltrials.gov) - P3 | N=1328 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Jan 2023 | Trial primary completion date: Jul 2024 ➔ Jan 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Meningococcal Infections

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (clinicaltrials.gov) - P3 | N=1480 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P3 trial • CNS Disorders • Infectious Disease • Meningococcal Infections

Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older. (PubMed, Infect Dis Ther) - "The benefit-risk profile for MenACYW-TT showed favorable seroresponse and seroprotection in individuals aged ≥ 2 years and no difference in risk criteria between MenACYW-TT and MCV4s. MenACYW-TT may provide an alternative to the standard-of-care for meningococcal disease prevention in those aged ≥ 12 months."

Benefit-risk assessment • Journal • Infectious Disease • Meningococcal Infections

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (clinicaltrials.gov) - P2 | N=75 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2023 ➔ Jul 2024 | Trial primary completion date: Jul 2023 ➔ Jul 2024

Trial completion date • Trial primary completion date • Oncology

Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial. (PubMed, Lancet Infect Dis) - P1 | "Pfs230D1 but not Pfs25 vaccine induces durable serum functional activity in Malian adults. Direct skin feed assays detect parasite transmission to mosquitoes but increased event rates are needed to assess vaccine effectiveness."

Journal • P1 data • Allergy • Immunology • Infectious Disease • Malaria

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children. (PubMed, Hum Vaccin Immunother) - P4 | "No serious adverse events were reported during the study period. MPV ACYW135 showed a non-inferior immunogenicity profile and a comparable reactogenicity profile to MCV-4 in Malian children aged 2-10 years.Clinical Trial Registration: NCT04450498."

Journal • CNS Disorders • Infectious Disease • Meningococcal Infections

"هناك عده تطعيمات تقي ضد الانواع الاكثر انتشارا من هذه البكتيريا وهي A,C,Y, W-135 من أشهرها تطعيم ميناكترا Menactra وهو تطعيم مترافق مع بكتيريا دفتيريا لإعطائه اربعه اضعاف الحمايه الناجمه من التطعيم القديم غير المترافق." (@guesswali)

MEQ00064: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (clinicaltrials.gov) - P3 | N=1528 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Meningococcal Infections • Pediatrics

MEQ00064: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (clinicaltrials.gov) - P3 | N=1528 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Meningococcal Infections • Pediatrics

Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali (clinicaltrials.gov) - P2 | N=1301 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Malaria

MET55: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (clinicaltrials.gov) - P3 | N=1482 | Recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Trial completion date: Sep 2023 ➔ Jul 2024 | Trial primary completion date: Sep 2023 ➔ Jul 2024

Trial completion date • Trial primary completion date • Infectious Disease • Meningococcal Infections

Vaccine Schedule Disparities Exist for Pediatric Patients with Sickle Cell Disease (ASH 2022) - "Meningococcal [MenACWY] vaccination: Mean±SD age at MenACWY initiation was 11.2±1.8 years (recommended age for patients with SCD is 2 months (MenACWY Menveo) or 24 months (MenACWY Menactra); recommended age for general population is 11 years). Adherence to SCD-specific vaccination age recommendations is poor. We found that patients with SCD were more likely to receive vaccines according to the general population vaccine schedule rather than the SCD-specific vaccine schedule. In addition, reliance on pediatricians to provide PPSV23 for satellite clinic patients resulted in lower PPSV23 vaccination rates among these patients."

Clinical • Genetic Disorders • Hematological Disorders • Infectious Disease • Meningococcal Infections • Pediatrics • Pneumococcal Infections • Pneumonia • Sickle Cell Disease

Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors (clinicaltrials.gov) - P4 | N=102 | Active, not recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Apr 2022 ➔ Apr 2024 | Trial primary completion date: Oct 2021 ➔ Oct 2023

Trial completion date • Trial primary completion date • CNS Disorders • Infectious Disease • Meningococcal Infections

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (clinicaltrials.gov) - P2 | N=75 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2022 ➔ Jul 2023 | Trial primary completion date: Jul 2022 ➔ Jul 2023

Trial completion date • Trial primary completion date • Oncology • Solid Tumor